Interested in virome sequencing on @Nanopore instruments? Check out our (@EpiTaxEvo) latest paper where we publish Twist-ONT, a modified protocol for the Twist Comprehensive Viral Research Panel (by @TwistBioscience) so that it can be used with ONT.
https://t.co/elxhP2qXtX
🧵1/7
Enjoying ESCMID Global 2026 in Munich. Thank you to everyone who visited my poster. If you missed it you can search for my name in the ESCMID app #ESCMIDGlobal2026
Interested in virome sequencing on @Nanopore instruments? Check out our (@EpiTaxEvo) latest paper where we publish Twist-ONT, a modified protocol for the Twist Comprehensive Viral Research Panel (by @TwistBioscience) so that it can be used with ONT.
https://t.co/elxhP2qXtX
🧵1/7
Interested in virome sequencing on @Nanopore instruments? Check out our (@EpiTaxEvo) latest paper where we publish Twist-ONT, a modified protocol for the Twist Comprehensive Viral Research Panel (by @TwistBioscience) so that it can be used with ONT.
https://t.co/elxhP2qXtX
🧵1/7
At the 8th Nordic Conference of Antiviral Treatments Strategies and Drug Resistance at the beautiful Norrlands Nation in Uppsala, arranged by my co-supervisor Johan Lennerstrand 🧪 #Science#Antivirals#HIV#SARSCoV2#Hepatitis#Virology
A summary of our recent study on SARS-CoV-2 and monoclonal antibodies was published in Physician's Weekly https://t.co/GyrxThXchX
#COVID19#SARSCoV2#Science
A summary of our recent study on SARS-CoV-2 and monoclonal antibodies was published in Physician's Weekly https://t.co/GyrxThXchX
#COVID19#SARSCoV2#Science
Happy to share our latest scientific article, “Dynamics of SARS-CoV-2 variants and mutations in Central Sweden between 2023 and 2024 and their potential implications on monoclonal antibodies pemivibart and sipavibart as PrEP in the region”.
#COVID19
https://t.co/Jac6OpJlkZ
🧵1
...and our next work: Comprehensive transcriptome assessment in PBMCs of post-COVID patients at a median follow-up of 28 months after a mild COVID infection: https://t.co/MbwIWU4Dtq